Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Takeda Pharmaceutical Co ( (JP:4502) ) has provided an update.
Takeda Pharmaceutical Co has revised its financial forecast for the fiscal year ending March 31, 2026, anticipating a decrease in revenue and profits due to factors such as generic erosion of VYVANSE sales in the U.S. and impairment charges. Despite these challenges, the company expects to offset some losses with cost savings from R&D and efficiency programs. The revised outlook reflects a strategic shift towards new product launches and a transition to a new phase of business operations.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a leading values-based, R&D-driven biopharmaceutical company focused on creating better health for people and a brighter future for the world. The company aims to discover and deliver life-transforming treatments in core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Average Trading Volume: 4,711,447
Technical Sentiment Signal: Buy
Current Market Cap: Yen6710.8B
For an in-depth examination of 4502 stock, go to TipRanks’ Overview page.